Delivery Order SPE2DR25D2213-SPE2DR26F6DBP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,981.41 on November 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,830.66 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award was made on November 24, 2025, under a firm fixed-price contract type with an ultimate completion date of November 25, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,792.62 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,020.90 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on December 9, 2025, with completion scheduled for December 10, 2025. This non-competitive, firm fixed-price delivery order represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply contract with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the delivery at its...
- The Defense Logistics Agency awarded a delivery order valued at $1,405.80 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. This order falls under...
- The Defense Logistics Agency awarded a $3,570.95 delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price contract with an ultimate completion date of December 10, 2025, with performance to be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award was competitively procured without a set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $4,966.59. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by September 18, 2025. The order is issued under AmerisourceBergen's Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $53,916.19 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was issued on October 8, 2025, with an ultimate completion date of October 9, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite...
- SPE2DR25D2213Indefinite Delivery Contract
- SPE2DR25D2213-SPE2DR26F6DBPDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,345.20 on December 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of December 16, 2025. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying medications, vaccines, medical devices, and healthcare commodities to support military and veteran healthcare systems. The company holds significant capacity as a prime vendor under DLA's Pharmaceutical Supply Chain, enabling it to fulfill diverse medical supply needs across multiple therapeutic domains. This specific delivery order for insulin products supports the Defense Health Agency and other government healthcare systems relying on the DLA's medical supply network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 12/14/25 |